• 약학회지
• /
• 제49권3호
• /
• pp.193-197
• /
• 2005

Procainamide is the drug of second choice (after lidocaine) in most coronary care units for the treatment of sustained ventricular arrhythmias associated with acute myocardial infarction. The purpose of this study was to develop the efficient assay method of procainamide in human plasma and to assess the pharmacokinetic profile of procainamide in healthy Korean volunteers. The pharmacokinetics of procainamide administered orally was evaluated after a dose of 250 mg. Procainamide in plasma was assayed using a specific HPLC method with UV absorbance at 275 nm. AUC was $4.58{\pm}0.90 {\mu}g/ml-hr$, $C_{max}\;1.34{\pm}0.39{\mu}g/ml$, $T_{max}\;1.06{\pm}0.34 hr$ and half-life $3.07\pm0.34 hr$. $T_{max}$ was slightly shorter than that in Caucasian (1-2 hr), whereas the half-life was similar to that in Caucasian (2.5-4.1 hr).